mRNA, RNA, and Vaccine Design

RNA and vaccine design combine sequence, structure, immunology, delivery, manufacturing, and population biology. AI helps with parts of that stack, not the whole stack at once.

Learning Objectives

• Separate antigen selection, RNA sequence design, delivery, and immune evaluation.
• Identify the experimental gates for RNA and vaccine programs.
• Apply the three-tier framework to claims about design speed.

TL;DR

RNA and vaccine AI is strongest when the model output is tied to a measurable endpoint: expression, stability, antigenicity, manufacturability, or immune response. Program success still depends on delivery, dosing, safety, and clinical evidence.

Introduction

Genome and protein models matter for vaccine and RNA design because they support antigen analysis, protein design, variant interpretation, and sequence optimization. AlphaFold 3 addresses biomolecular interaction prediction (Abramson et al., 2024). Evo and AlphaGenome illustrate the move toward long-context sequence models (Nguyen et al., 2024; Avsec et al., 2026).

Demonstrated

Demonstrated capability includes protein antigen modeling, epitope-informed design support, and sequence-to-function modeling for selected genomic and molecular outputs. AlphaFold 3 demonstrated interaction modeling relevant to antigen-antibody and protein-nucleic acid questions (Abramson et al., 2024). Evo demonstrated sequence modeling across DNA, RNA, and proteins in the indexed Science report (Nguyen et al., 2024).

Evidence Anchor	What It Supports	Practical Constraint
AlphaFold 3	Biomolecular interaction structure prediction	Immune response is not settled by structure alone
Evo	Long-context biological sequence modeling	RNA therapeutic behavior requires delivery and assay data
FDA drug AI materials	Regulatory attention to AI in drug and biologic development	Context of use drives evidentiary needs

Theoretical

Theoretical capability includes integrated vaccine design systems that jointly model antigen structure, immune escape, expression, delivery, and population-level strain coverage. Such systems require data across immunology, manufacturing, and clinical outcomes.

Beyond Current Capabilities

Beyond current capabilities includes reliable vaccine design from sequence surveillance alone. Immunogenicity, durability, safety, delivery, and real-world effectiveness require experiments and trials.

Practice Notes

• Keep antigen modeling separate from immune-response prediction.
• Validate expression, stability, and formulation before immunogenicity claims.
• Use neutralization, cellular immunity, and safety assays as separate evidence layers.
• Avoid fixed timeline claims unless a specific program supplies verified dates.